Faisal Humayun

Faisal Humayun

Expertise: Oil and Gas, Electric Vehicles, Emerging Growth Stories

Education: Bachelor of Science, MBA with Specialization in Finance

About Faisal:
Faisal Humayun is an MBA in Finance and a senior research analyst with 14 years of experience in the field of equity, credit, industry and economic research. While working as a senior analyst, he has been involved in financial modelling, valuation analysis and credit rating.

As a freelancer, Faisal has authored over 1,500 articles for various publications that include Seeking Alpha, GuruFocus, Motley Fool, Trading Ideas and Red Pulse. His primary focus is on fundamental analysis using the top-down as well as bottom-up approach to stock selection.

Faisal is also an active trader with focus on price action trading strategy. A combination of long-term investing and short-term trading has produced decent results in a decade long exposure to equity markets. However, his favorite asset class is precious metals.

Additionally, Faisal has been researching cryptocurrencies in the last few quarters. His focus is not on the blue-chip coins, but on emerging altcoins that can be value creators.

You can learn more about Faisal at his profile on LinkedIn.

Recent Articles

3 Crypto Stocks to Buy for 100% Returns as Bitcoin Consolidates

These are the crypto stocks to buy as they represent attractively valued companies with a robust growth and cash flow upside outlook

Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation

These are the blue-chip stocks to buy as they represent fundamentally strong companies with robust free cash flow visibility

3 New IPOs to Buy for 20-Bagger Returns by 2030

Hot, high-growth IPO stocks to buy represent promising early-stage companies with visibility for multi-fold growth in revenue.

3 EV Stocks to Sell in July Before They Crash & Burn

These are the EV stocks to sell as they represent companies with poor fundamentals and significant cash burn.

3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns

These are the clinical-stage biotech stocks to buy, as they represent companies with an attractive product pipeline.